AdultPediatricGeriatricDosage Forms & Strengths injection, solution 0.5mL single-dose vial Each 0.5-mL dose contains 10 mcg each of meningococcal A, C, W, and Y polysaccharide antigens conjugated to ~55 mcg tetanus toxoid protein carrier; also contains 3.35 mg sodium chloride (0.67%) and 1.23 mg sodium acetate (30 mM) No preservative or adjuvant is added Meningococcal Immunization Indicated for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged ≥2 years Primary vaccination: 0.5 mL IM x1 dose Booster for individuals at continued risk Consider in individuals aged ≥15 yr if at least 4 yr have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine 0.5 mL IM x1 dose Dosing Considerations Does not prevent N meningitidisserogroup B diseaseDosage Forms & Strengths injection, solution 0.5mL single-dose vial Each 0.5-mL dose contains 10 mcg each of meningococcal A, C, W, and Y polysaccharide antigens conjugated to ~55 mcg tetanus toxoid protein carrier; also contains 3.35 mg sodium chloride (0.67%) and 1.23 mg sodium acetate (30 mM) No preservative or adjuvant is added Meningococcal Immunization Indicated for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged ≥2 years <2 years: Safety and efficacy not established 2 years or older Primary vaccination: 0.5 mL IM x1 dose Booster for individuals at continued risk Consider in individuals aged ≥15 yr if at least 4 yr have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine 0.5 mL IM x1 dose Dosing Considerations Does not prevent N meningitidisserogroup B diseaseVaccine recipients aged ≥65 yr had lower geometric mean antibody titers and seroresponse rates for all serogroups compared with recipients aged 56-64 yrInteraction CheckerEnter a drug name and meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (3)elivaldogene autotemcelelivaldogene autotemcel, meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .ofatumumab SCofatumumab SC decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.teplizumabteplizumab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.Monitor Closely (6)cyclosporinecyclosporine decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .delandistrogene moxeparvovecdelandistrogene moxeparvovec, meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines.satralizumabsatralizumab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. .tralokinumabtralokinumab will decrease the level or effect of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines.ublituximabublituximab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells.voclosporinvoclosporin decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.Minor (0)cyclosporineMonitor Closely (1)cyclosporine decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .delandistrogene moxeparvovecMonitor Closely (1)delandistrogene moxeparvovec, meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines.elivaldogene autotemcelSerious - Use Alternative (1)elivaldogene autotemcel, meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .ofatumumab SCSerious - Use Alternative (1)ofatumumab SC decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.satralizumabMonitor Closely (1)satralizumab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. .teplizumabSerious - Use Alternative (1)teplizumab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.tralokinumabMonitor Closely (1)tralokinumab will decrease the level or effect of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines.ublituximabMonitor Closely (1)ublituximab decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells.voclosporinMonitor Closely (1)voclosporin decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment. >10% All Grades Children aged 2-9 yr Injection site pain (38.6%) Injection site erythema (22.6%) Malaise (21.1%) Myalgia (20.1%) Injection site swelling (13.8%) Headache (12.5%) Adolescents aged 10-17 yr Injection site pain (45.2%) Myalgia (35.3%) Headache (30.2%) Malaise (26%) Adults aged 18-55 yr Injection site pain (41.9%) Myalgia (35.6%) Headache (29%) Malaise (22.9%) Adults aged 56 yr or older Injection site pain (25.5%) Myalgia (21.9%) Headache (19%) Malaise (14.5%) 1-10% All Grades Children aged 2-9 yr Fever (1.9%) Adolescents aged 10-17 yr Injection site swelling (5.4%) Injection site erythema (5%) Fever (1.4%) Adults aged 18-55 yr Injection site erythema (5.1%) Injection site swelling (4.3%) Fever (1.4%) Adults aged 56 yr or older Injection site erythema (5.2%) Injection site swelling (4.5%) Fever (2.1%) 1-10% Grade 3 Children aged 2-9 yr Injection site erythema (3.1%) Malaise (1.8%) Injection site swelling (1.4%) Adolescents aged 10-17 yr Malaise (2.2%) Headache (1.8%) Myalgia (1.6%) Injection site pain (1.4%) Adults aged 18-55 yr Myalgia (3.6%) Headache (2.9%) Malaise (2.9%) Injection site pain (1.9%) Adults aged 56 yr or older Myalgia (1.6%) Malaise (1.4%) <1% Grade 3 Children aged 2-9 yr Injection site pain (0.6%) Myalgia (0.4%) Adolescents aged 10-17 yr Injection site erythema (0.4%) Fever (0.4%) Injection site swelling (0.2%) Adults aged 18-55 yr Injection site erythema (0.3%) Injection site swelling (0.2%) Fever (0.1%) Adults aged 56 yr or older Injection site pain (0.7%) Headache (0.7%) Injection site erythema (0.2%) Fever (0.2%) Contraindications Severe allergic reaction to any component of the vaccine after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine Cautions Acute allergic reactions may occur; appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following vaccine administration Syncope can occur following (or before) administration; assure procedures are in place to prevent falling or injury Guillain-Barré syndrome reported in temporal relationship following administration of another meningococcal quadrivalent polysaccharide conjugate vaccines Immunization with MenQuadfi does not substitute for routine tetanus immunization Vaccination may not protect all vaccine recipients Altered immunocompetence Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses Persons with certain complement deficiencies or those receiving drugs that inhibit terminal complement activation (eg, eculizumab, ravulizumab) are at increased risk for invasive disease caused by N meningitidis Drug interaction overview Coadministration with other vaccines Lower geometric mean antibody concentrations for antibodies to the pertussis antigens filamentous hemagglutinin, pertactin, and fimbriae observed when coadministered with Tdap and HPV, compared with concomitant administration of Tdap and HPV (without MenQuadfi) Immunosuppressive treatment Immunosuppressive therapies may reduce the immune response to meningococcal vaccine Pregnancy Data are not available for exposure during pregnancy in humans Pregnancy exposure registry that monitors pregnancy outcomes in females exposed during pregnancy; 1-800-822-2463 Animal data Female rabbits received a human dose by IM injection on 5 occasions: 30 days and 10 days before mating, gestation days 6, 12, and 27 No adverse effects on preweaning development up to postnatal day 35 were observed No vaccine-related fetal malformations or variations were observed Lactation Unknown if excreted in human milk Data are not available to assess effects on breastfed infants or on milk production/excretionPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.